{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T15:57:17Z","timestamp":1776959837813,"version":"3.51.4"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc","award":["W81XWH-11-2-0174"],"award-info":[{"award-number":["W81XWH-11-2-0174"]}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.nano.2018.12.001","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T03:10:44Z","timestamp":1545102644000},"page":"206-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Design and characterization of a self-assembling protein nanoparticle displaying HIV-1 Env V1V2 loop in a native-like trimeric conformation as vaccine antigen"],"prefix":"10.1016","volume":"16","author":[{"given":"Christopher P.","family":"Karch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar B.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney A.","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson L.","family":"Michael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary R.","family":"Matyas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgane","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Burkhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Beck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2018.12.001_bb0005","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nano.2018.12.001_bb0010","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nano.2018.12.001_bb0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.immuni.2012.11.011","article-title":"Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.nano.2018.12.001_bb0020","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.1128\/JVI.00156-14","article-title":"HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities","volume":"88","author":"Pollara","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2018.12.001_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005817","article-title":"Antibody-Mediated Internalization of Infectious HIV-1 virions differs among antibody isotypes and subclasses","volume":"12","author":"Tay","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.nano.2018.12.001_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143895","article-title":"Identification of new regions in HIV-1 gp120 variable 2 and 3 loops that bind to alpha4beta7 Integrin Receptor","volume":"10","author":"Peachman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.nano.2018.12.001_bb0035","doi-asserted-by":"crossref","first-page":"e01843-17","DOI":"10.1128\/JVI.01843-17","article-title":"HIV-1 Envelope glycoproteins from diverse clades differentiate antibody responses and durability among vaccinees","volume":"92","author":"Yates","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2018.12.001_bb0040","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1089\/aid.2012.0103","article-title":"The Thai phase III HIV Type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120","volume":"28","author":"Karasavvas","year":"2012","journal-title":"AIDS Res Hum Retrovir"},{"key":"10.1016\/j.nano.2018.12.001_bb0045","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1128\/JVI.00754-15","article-title":"The V1V2 region of HIV-1 gp120 forms a five-stranded beta barrel","volume":"89","author":"Pan","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2018.12.001_bb0050","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nri2801","article-title":"Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design","volume":"10","author":"Zolla-Pazner","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.nano.2018.12.001_bb0055","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1586\/14760584.2014.951335","article-title":"The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development","volume":"13","author":"O'Connell","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.nano.2018.12.001_bb0060","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature11519","article-title":"Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2","volume":"490","author":"Rolland","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.nano.2018.12.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003973","article-title":"Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial","volume":"11","author":"Edlefsen","year":"2015","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.nano.2018.12.001_bb0070","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/jvi.68.1.400-410.1994","article-title":"Presentation of native epitopes in the V1\/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains","volume":"68","author":"Kayman","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2018.12.001_bb0075","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1128\/jvi.67.8.4932-4944.1993","article-title":"Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120","volume":"67","author":"McKeating","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2018.12.001_bb0080","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.nano.2018.12.001_bb0085","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"Walker","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.nano.2018.12.001_bb0090","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1128\/JVI.03451-14","article-title":"Single-chain soluble BG505.SOSIP gp140 trimers as structural and antigenic mimics of mature closed HIV-1 Env","volume":"89","author":"Georgiev","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2018.12.001_bb0095","doi-asserted-by":"crossref","first-page":"12041","DOI":"10.1038\/ncomms12041","article-title":"Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles","volume":"7","author":"He","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.nano.2018.12.001_bb0100","doi-asserted-by":"crossref","first-page":"11947","DOI":"10.1073\/pnas.1507793112","article-title":"Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens","volume":"112","author":"Julien","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nano.2018.12.001_bb0105","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/JVI.03473-14","article-title":"A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene","volume":"89","author":"Pugach","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2018.12.001_bb0110","doi-asserted-by":"crossref","DOI":"10.1126\/science.aac4223","article-title":"HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers","volume":"349","author":"Sanders","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.nano.2018.12.001_bb0115","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.celrep.2015.03.047","article-title":"Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design","volume":"11","author":"Sharma","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.nano.2018.12.001_bb0120","doi-asserted-by":"crossref","first-page":"10993","DOI":"10.1128\/JVI.01403-16","article-title":"Rationally designed vaccines rargeting the V2 region of HIV-1 gp120 induce a focused, cross-clade-reactive, biologically functional antibody response","volume":"90","author":"Zolla-Pazner","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2018.12.001_bb0125","doi-asserted-by":"crossref","first-page":"e01796-17","DOI":"10.1128\/JVI.01796-17","article-title":"A trimeric HIV-1 envelope gp120 immunogen induces potent and broad anti-V1V2 loop antibodies against HIV-1 in rabbits and rhesus macaques","volume":"92","author":"Jones","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2018.12.001_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.05.001","article-title":"Vaccine technologies: From whole organisms to rationally designed protein assemblies","volume":"120","author":"Karch","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.nano.2018.12.001_bb0135","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.nano.2006.04.007","article-title":"Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles","volume":"2","author":"Raman","year":"2006","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nano.2018.12.001_bb0140","first-page":"126794","article-title":"A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection","volume":"2011","author":"Babapoor","year":"2011","journal-title":"Influenza Res Treat"},{"key":"10.1016\/j.nano.2018.12.001_bb0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41541-017-0024-6","article-title":"Protein nanovaccine confers robust immunity against Toxoplasma","volume":"2","author":"El Bissati","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.nano.2018.12.001_bb0150","doi-asserted-by":"crossref","first-page":"7268","DOI":"10.4049\/jimmunol.0901957","article-title":"A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria","volume":"183","author":"Kaba","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.nano.2018.12.001_bb0155","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.vaccine.2017.12.001","article-title":"Self-assembling protein nanoparticles with built-in flagellin domains increases protective efficacy of a Plasmodium falciparum based vaccine","volume":"36","author":"Kaba","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2018.12.001_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048304","article-title":"Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine","volume":"7","author":"Kaba","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.nano.2018.12.001_bb0165","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.nano.2016.08.030","article-title":"Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge","volume":"13","author":"Karch","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nano.2018.12.001_bb0170","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1747-0285.2008.00746.x","article-title":"Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine","volume":"73","author":"Pimentel","year":"2009","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.nano.2018.12.001_bb0175","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1016\/j.vaccine.2017.02.040","article-title":"Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum circumsporozoite protein delivered in three Army liposome formulation adjuvants","volume":"35","author":"Seth","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2018.12.001_bb0180","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12951-017-0295-0","article-title":"The use of a P. falciparum specific coiled-coil domain to construct a self-assembling protein nanoparticle vaccine to prevent malaria","volume":"15","author":"Karch","year":"2017","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.nano.2018.12.001_bb0185","doi-asserted-by":"crossref","first-page":"310-305","DOI":"10.1016\/j.coi.2012.03.008","article-title":"Adjuvants for human vaccines","volume":"24","author":"Alving","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.nano.2018.12.001_bb0190","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1016\/j.vaccine.2015.09.001","article-title":"Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21","volume":"33","author":"Beck","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2018.12.001_bb0195","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jconrel.2018.02.006","article-title":"Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex","volume":"275","author":"Beck","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2018.12.001_bb0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41541-017-0013-9","article-title":"Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant","volume":"2","author":"Torres","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.nano.2018.12.001_bb0205","doi-asserted-by":"crossref","first-page":"E3095","DOI":"10.1073\/pnas.1500851112","article-title":"Accurate secondary structure prediction and fold recognition for circular dichroism spectroscopy","volume":"112","author":"Micsonai","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nano.2018.12.001_bb0210","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/QAD.0b013e328360db2d","article-title":"The rapidly expanding CRF01_AE epidemic in China is driven by multiple lineages of HIV-1 viruses introduced in the 1990s","volume":"27","author":"Feng","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.nano.2018.12.001_bb0215","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1021\/bi702509d","article-title":"Impact of the enfuvirtide resistance mutation N43D and the associated baseline polymorphism E137K on peptide sensitivity and six-helix bundle structure","volume":"47","author":"Bai","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.nano.2018.12.001_bb0220","doi-asserted-by":"crossref","first-page":"161092","DOI":"10.1098\/rsos.161092","article-title":"Classification of self-assembling protein nanoparticle architectures for applications in vaccine design","volume":"4","author":"Indelicato","year":"2017","journal-title":"R Soc Open Sci"},{"key":"10.1016\/j.nano.2018.12.001_bb0225","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.bpj.2015.10.057","article-title":"Principles Governing the Self-Assembly of Coiled-Coil Protein Nanoparticles","volume":"110","author":"Indelicato","year":"2016","journal-title":"Biophys J"},{"key":"10.1016\/j.nano.2018.12.001_bb0230","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1128\/jvi.65.9.4832-4838.1991","article-title":"Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies","volume":"65","author":"Xu","year":"1991","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2018.12.001_bb0235","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1128\/JVI.01023-12","article-title":"Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family","volume":"86","author":"Bonsignori","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2018.12.001_bb0240","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.immuni.2017.03.017","article-title":"A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic beta-Hairpin Structure","volume":"46","author":"Lee","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.nano.2018.12.001_bb0245","doi-asserted-by":"crossref","first-page":"10163","DOI":"10.1128\/JVI.01161-13","article-title":"Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking","volume":"87","author":"Schiffner","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2018.12.001_bb0250","doi-asserted-by":"crossref","first-page":"12111","DOI":"10.1073\/pnas.1204533109","article-title":"HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120","volume":"109","author":"Kovacs","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nano.2018.12.001_bb0255","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40794-017-0050-4","article-title":"Prospecting for an HIV vaccine","volume":"3","author":"Brett-Major","year":"2017","journal-title":"Trop Dis Travel Med Vaccines"},{"key":"10.1016\/j.nano.2018.12.001_bb0260","doi-asserted-by":"crossref","first-page":"11007","DOI":"10.1128\/JVI.01409-16","article-title":"Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits","volume":"90","author":"Jiang","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2018.12.001_bb0265","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12977-015-0210-4","article-title":"Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity","volume":"12","author":"Sliepen","year":"2015","journal-title":"Retrovirology"},{"key":"10.1016\/j.nano.2018.12.001_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2017.04.011","article-title":"Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop","volume":"46","author":"Cale","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.nano.2018.12.001_bb0275","doi-asserted-by":"crossref","first-page":"10213","DOI":"10.1128\/JVI.72.12.10213-10217.1998","article-title":"A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein","volume":"72","author":"Jiang","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.nano.2018.12.001_bb0280","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nature10696","article-title":"Structure of HIV-1 gp120 V1\/V2 domain with broadly neutralizing antibody PG9","volume":"480","author":"McLellan","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.nano.2018.12.001_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087572","article-title":"Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection","volume":"9","author":"Zolla-Pazner","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.nano.2018.12.001_bb0290","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/QAI.0000000000001675","article-title":"Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones","volume":"78","author":"Chenine","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.nano.2018.12.001_bb0295","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1111\/febs.13530","article-title":"The HIV glycan shield as a target for broadly neutralizing antibodies","volume":"282","author":"Doores","year":"2015","journal-title":"FEBS J"},{"key":"10.1016\/j.nano.2018.12.001_bb0300","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.celrep.2017.04.013","article-title":"Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation","volume":"19","author":"Zhou","year":"2017","journal-title":"Cell Rep"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963418305677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963418305677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:09:16Z","timestamp":1761548956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963418305677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":60,"alternative-id":["S1549963418305677"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2018.12.001","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and characterization of a self-assembling protein nanoparticle displaying HIV-1 Env V1V2 loop in a native-like trimeric conformation as vaccine antigen","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2018.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}